SODIUM SUCCINATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SODIUM SUCCINATE (SODIUM SUCCINATE).
Sodium succinate is a salt of succinic acid, which serves as an intermediate in the tricarboxylic acid (TCA) cycle. It acts as a metabolic supplement, enhancing cellular respiration and energy production by providing substrate for the TCA cycle. It also exhibits antioxidant properties by scavenging free radicals.
| Metabolism | Sodium succinate is metabolized via the tricarboxylic acid (TCA) cycle to carbon dioxide and water, with energy release. No specific cytochrome P450 enzymes are involved. |
| Excretion | Renal excretion of unchanged drug; less than 5% biliary/fecal. |
| Half-life | 5-10 minutes; rapid elimination limits systemic effects. |
| Protein binding | Not significantly protein bound (<5%). |
| Volume of Distribution | 0.3-0.5 L/kg; limited to extracellular fluid. |
| Bioavailability | Not applicable; administered intravenously; no oral bioavailability due to rapid metabolism. |
| Onset of Action | Intravenous: within 30 seconds to 1 minute. |
| Duration of Action | 5-10 minutes; brief duration due to rapid metabolism and excretion. |
No established standard dosing for sodium succinate as a therapeutic agent; it is used as a pharmaceutical excipient or buffering agent in intravenous formulations. For buffering purposes, typical concentrations range from 0.5% to 2% in injection solutions, administered intravenously at rates adjusted per clinical need.
| Dosage form | INJECTABLE |
| Renal impairment | No renal dose adjustment data available; sodium succinate is not renally excreted in significant amounts and is unlikely to accumulate in renal impairment, but caution with sodium load in severe renal dysfunction. |
| Liver impairment | No hepatic dose adjustment data available; no expected impact of hepatic impairment on sodium succinate disposition. |
| Pediatric use | No established pediatric dosing; use as excipient follows adult concentration guidelines with weight-based fluid calculations. |
| Geriatric use | No specific geriatric dose adjustment; consider sodium load and renal function in elderly patients with comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SODIUM SUCCINATE (SODIUM SUCCINATE).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown; sodium succinate is endogenous and likely present in milk at low concentrations; caution advised. |
| Teratogenic Risk | No human or animal data available; sodium succinate is a Krebs cycle intermediate with essential metabolic roles; theoretical fetal risk is low, but administration during pregnancy should be cautious and only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to sodium succinate; severe hypernatremia; edema with sodium retention; severe hypertension; and in patients with metabolic alkalosis.
| Precautions | Use with caution in patients with renal impairment due to sodium content; monitor serum sodium levels. May cause transient hypotension or hypertension. Avoid rapid intravenous administration to prevent adverse cardiac events. |
Loading safety data…
| No specific monitoring requirements; standard maternal vital signs and fetal heart rate monitoring during administration if used in obstetric emergencies. |
| Fertility Effects | No known effects on fertility; not studied. |